Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

pay.thelady61 shared this article with you from Inoreader Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC Via ClinicalTrials.gov: HEAD AND NECK | Open Studies | updated in the last 14 days Condition:   Squamous Cell Carcinoma of the Head and Neck Interventions:   Drug: CMAB819;   Drug: Nivolumab Sponsor:   Taizhou Mabtech Pharmaceutical Co.,Ltd Recruiting View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.